Fennec Pharmaceuticals Inc.
NCM: FENCLive Quote
📈 ZcoreAI Score
Our AI model analyzes Fennec Pharmaceuticals Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get FENC Z-Score →About Fennec Pharmaceuticals Inc.
Healthcare
Biotechnology
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
📊 Fundamental Analysis
Fennec Pharmaceuticals Inc. demonstrates a profit margin of -21.8%, which is below the sector average, suggesting competitive pressure.
The company recently reported 73.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -65.8%, which indicates that capital utilization is currently under pressure.
At a current price of $5.81, FENC currently trades near the bottom of its 52-week range (17%), indicating potential value or weakness (Range: $4.98 - $9.92).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$200.30M
Trailing P/E
--
Forward P/E
6.42
Beta (5Y)
0.93
52W High
$9.92
52W Low
$4.98
Avg Volume
166K
Day High
Day Low